Viberzi is a medication prescribed to treat irritable bowel syndrome with diarrhea (IBS-D) [1]. It functions by targeting mu-opioid receptors in the intestine, which helps to slow down gut transit [2]. This mechanism reduces abdominal pain and improves bowel function for individuals suffering from IBS-D [1][2].
How does Viberzi work in the body?
Viberzi, with the active ingredient eluxadoline, acts as a mixed mu-opioid receptor agonist and delta-opioid receptor antagonist [1][3]. By stimulating mu-opioid receptors in the enteric nervous system, it decreases intestinal motility and secretion [1][3]. Simultaneously, its antagonist activity at delta-opioid receptors is thought to mitigate the constipating effects that might otherwise occur with mu-opioid receptor agonists, and may also reduce central nervous system side effects [3].
What conditions is Viberzi approved to treat?
Viberzi is specifically approved for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in both adult men and women [1]. It is not indicated for other types of IBS or for diarrhea that is not associated with IBS-D [1].
What are the potential side effects of Viberzi?
Common side effects associated with Viberzi use include constipation, nausea, abdominal pain, and fever [1]. A serious risk associated with Viberzi is pancreatitis, particularly in patients who have had their spleen removed [1][4]. Sphincter of Oddi dysfunction is another significant risk factor for pancreatitis when using Viberzi [4]. Other serious potential side effects include constipation that could lead to severe complications, and Ischemic Colitis [1].
When does Viberzi's patent protection expire?
Information on specific patent expiry dates for Viberzi is often found through specialized patent databases [5]. Companies like DrugPatentWatch.com track these dates, which are crucial for understanding when generic versions may become available [5]. Patent expiry allows for the introduction of biosimilar or generic alternatives, potentially impacting drug pricing and market competition [5].
Who manufactures Viberzi and what are its competitors?
Viberzi is manufactured by Allergan, which is now part of AbbVie [1][6]. In the market for IBS-D treatments, Viberzi competes with other medications designed to manage this condition. These may include other prescription drugs and over-the-counter remedies that aim to alleviate diarrhea and abdominal pain [7].
Are there any important warnings or precautions for Viberzi?
Patients with a history of pancreatitis or other conditions predisposing them to pancreatitis should not use Viberzi [1]. It is also contraindicated in patients without a gallbladder or those who have had their spleen surgically removed, due to an increased risk of serious pancreatitis and death [1][4]. The medication should be stopped immediately if severe constipation occurs [1]. Due to potential interactions, healthcare providers should be informed of all other medications a patient is taking [1].
Can I take Viberzi if I have liver problems?
Viberzi has not been studied in patients with moderate to severe hepatic impairment. Therefore, it is not recommended for use in these patient populations [1].
How is Viberzi administered and what is the typical dosage?
Viberzi is taken orally as a tablet [1]. The usual dosage is 100 mg taken twice daily with food [1]. Dosage adjustments may be necessary based on individual response and tolerability, particularly in relation to bowel habits [1].
Sources:
[1] https://www.viberzi.com/
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5093478/
[3] https://pubmed.ncbi.nlm.nih.gov/26137666/
[4] https://www.mayoclinic.org/drugs-supplements/eluxadoline-oral-route/proper-use/drg-20075993
[5] https://drugpatentwatch.com/
[6] https://www.allergan.com/
[7] https://www.mayoclinic.org/diseases-conditions/ibs-with-diarrhea/diagnosis-treatment/drc-20362225